Last reviewed · How we verify
doxorubicin, docetaxel, tamoxifen
doxorubicin, docetaxel, tamoxifen is a Small molecule drug developed by GBG Forschungs GmbH. It is currently in Phase 2 development.
At a glance
| Generic name | doxorubicin, docetaxel, tamoxifen |
|---|---|
| Sponsor | GBG Forschungs GmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (PHASE3)
- Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)
- A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (PHASE3)
- Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes (PHASE3)
- Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB) (NA)
- Neoadjuvant Treatment of Breast Cancer
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- doxorubicin, docetaxel, tamoxifen CI brief — competitive landscape report
- doxorubicin, docetaxel, tamoxifen updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI
Frequently asked questions about doxorubicin, docetaxel, tamoxifen
What is doxorubicin, docetaxel, tamoxifen?
doxorubicin, docetaxel, tamoxifen is a Small molecule drug developed by GBG Forschungs GmbH.
Who makes doxorubicin, docetaxel, tamoxifen?
doxorubicin, docetaxel, tamoxifen is developed by GBG Forschungs GmbH (see full GBG Forschungs GmbH pipeline at /company/gbg-forschungs-gmbh).
What development phase is doxorubicin, docetaxel, tamoxifen in?
doxorubicin, docetaxel, tamoxifen is in Phase 2.